Nestlé Expands Functional Nutrition Portfolio to Support GLP-1 Users
Nestlé is strengthening its position in the rapidly growing functional nutrition category with the launch of a new product suite designed specifically for consumers using GLP-1 medications. The move reflects rising demand for tailored nutritional solutions as medications like Ozempic and Wegovy, originally developed for type 2 diabetes, become increasingly popular for weight management.
With the global surge in GLP-1 use—reportedly projected to reach 31.5 million users in the U.S. alone by 2030—Nestlé’s product innovation signals a strategic alignment with evolving dietary needs. GLP-1 drugs often suppress appetite, which can lead to nutrient deficiencies if not managed carefully. Nestlé’s new range aims to address this nutritional gap, providing convenient options that support healthy weight loss and muscle maintenance.
Science-Backed Nutrition for Modern Lifestyles
Branded under Nestlé’s Health Science division, the range includes GLP-1-focused offerings from brands such as Optifast, Boost, and Orgain. The functional products are formulated with high-quality protein, fiber, and essential vitamins, catering to consumers who may under-eat or struggle to meet daily nutritional requirements while on appetite-suppressing therapies.
The company has emphasized that these products are designed to complement—not replace—medical treatment, positioning them as part of a broader health and wellness strategy. In addition to shelf-stable meal replacements and shakes, Nestlé plans to continue expanding the portfolio based on user feedback and clinical research.
Targeting a Converging Wellness and Weight Management Segment
Nestlé’s entry into GLP-1 nutritional solutions also reflects broader consumer interest in proactive health. With weight management products outpacing overall food and beverage category growth, this move allows Nestlé to tap into a category experiencing robust expansion while reinforcing its position in high-growth, science-driven wellness segments.
“We’re witnessing a fundamental shift in how consumers manage their health, and nutrition plays an essential role,” said Anna Mohl, CEO of Nestlé Health Science. “Our aim is to provide targeted, effective products that support individuals using GLP-1 medications on their health journey.”
This expansion aligns with Nestlé’s long-term strategy to invest in health science and personalized nutrition